Abstract
Introduction
Acute kidney injury (AKI) is a complex disorder manifested by a rapid loss of renal function that results in retention of metabolic waste products.(1) A disease that primarily afflicts hospitalized patients, the incidence of AKI has steadily increased over the past decade, and while mortality has fallen with advances in renal replacement therapy (RRT), AKI still confers significant morbidity and mortality. (2) (3) (4) Several recent large studies of medical administrative databases have shown that in-hospital mortality for patients who develop AKI ranges from 20-28%; for those who require RRT, the mortality is higher, ranging from 28-33%. (3) (4) (5) Currently, there are no effective therapies to treat AKI. The present standard of care is to remove any potential instigating factors, optimize volume status and provide supportive care to allow renal function to recover.(1) As such, the ability to identify high-risk patients and potentially prevent AKI becomes crucial.
The current literature maintains that a patient's risk for AKI depends on a combination of acute insults and chronic co-morbidities. Acute risk factors include volume depletion, exposure to nephrotoxic agents or drugs such as aminoglycosides or radiocontrast dye, surgery, and the presence of the systemic inflammatory response syndrome or sepsis.(6-9) Chronic risk factors include advanced age, chronic kidney disease (CKD), diabetes and congestive heart failure. (9, 10) However, models using these traditional risk factors remain inadequate. (6, 7, (11) (12) (13) (14) Two patients with identical clinical risk factors often react differently to the same insult; one may suffer no harm while the other may require RRT. Furthermore, for those who develop RRT-requiring AKI, we as clinicians remain unable to predict which patients will progress to chronic dialysis and which will recover kidney function.
Consequently, there are likely to be clinically unobservable risk factors that contribute to one's susceptibility to AKI. Our understanding of epithelial, vascular and immune responses in kidney injury makes it likely that genetic variability in regulatory elements of these responses plays a major role in determining one's risk of AKI, given identical risk factors. This has been seen in other complex diseases, such as the discovery of a single nucleotide polymorphism (SNP) in complement factor H as a risk factor for age-related macular degeneration.(15) While there have not been any animal studies looking specifically at genetic polymorphisms and their impact on an organism's response to AKI, there has been strong evidence for differential gene expression in the murine model of AKI. (16) A genetic polymorphism that would alter that pattern of gene expression would hence change the reaction of an organism or individual cell to an acute insult, thus making such polymorphisms a plausible risk factor for AKI.
In AKI, genetic variation in inflammatory cytokines such as Tumor Necrosis Factor-alpha (TNF-) and Interleukin-6 (IL-6) have recently been proposed as risk factors. (13, (17) (18) (19) (20) This is due to the role of inflammatory mediators in the pathophysiology of AKI, especially with ischemia and sepsis. (1, 21, 22) Genetic variations of vasomotor regulatory proteins, such as angiotensin converting enzyme (ACE) and endothelial nitric oxide synthase (eNOS), have also been investigated given the importance of vascular reactivity in the pathogenesis of AKI. (13, 21, (23) (24) (25) However, it remains difficult to ascertain which polymorphisms are truly associated with AKI.(26) False positive reports are common in genetic association studies, and the plausibility of an association is highly dependent on the quality of the studies involved.(27) Therefore, we conducted this systematic review to evaluate the quality of published studies on genetic associations with AKI, and to ascertain if the current evidence demonstrates any polymorphism to be conclusively associated with AKI.
Hypothesis and Aims
The primary hypothesis of this study is as follows, that a given patient's risk of developing acute kidney injury after a known insult, such as ischemia, sepsis or nephrotoxic agents, is dependent on that patient's genetic makeup. That is, genetic polymorphisms that are commonly found in the population at large will render a patient either more or less susceptible to AKI. Our aim is to do a systematic review of the current existing literature on the topic and, where possible, perform a quality analysis of the studies found in order to determine the plausibility of the reported associations. Where appropriate, we plan to perform a meta-analysis to provide pooled odds ratios and relative risks.
Methods

Literature Selection
Studies were selected by searching MEDLINE, EMBASE, HuGEnet, SCOPUS and Web of Science for articles listed from 1950 up until December 2007. We used terms such as "acute kidney injury", "acute renal insufficiency" and "acute renal failure" in combination with "genetic variation" and "polymorphism" as our search criteria. We included many terms in our search to achieve as high sensitivity as possible.
Search terms were chosen by using keywords found in the Medical Subject Headings (MeSH) controlled language. This is the search language that is used by MEDLINE to index all articles found within that database. The MeSH language tree was searched for any and all keywords or categories associated with AKI or genetics. Where possible, we excluded more specific terms by moving up the MeSH language tree in order to use more inclusive search terms.
For example, "genetic polymorphism" was included under "variation (genetics)", and "acute tubular necrosis" was included within "acute kidney failure." EMBASE search terms were found by matching MeSH terms to their equivalent EMTREE terms, a different controlled language that is used within the EMBASE database. Web of Science, SCOPUS and HuGEnet do not use controlled languages and therefore a larger number of relevant keywords were used. Our exact criteria are listed in Table 1 below. A strict set of selection criteria were then applied to the articles found by the search. We included any original study that pertained to associations between AKI and human gene polymorphisms or variability. Our exclusion criteria were the following: 1) Studies with less than 20 subjects; 2) Case reports and series; 3) Animal studies; 4) Outpatient studies; 5) Studies where the etiology of AKI was HUS/TTP, ischemia/reperfusion of a kidney allograft, IgA nephropathy or glomerulonephritis.
The reasons for each of the exclusion criteria are as follows. For criteria 1), the effect found in a study with fewer than 20 subjects was as likely to be from chance as an actual effect, despite achieving statistical significance. Therefore, all such small studies were excluded. Likewise, case reports and series would likely have small numbers and also would not be able to show an association, given that no comparison would have been made to a control group or an at risk population. Animal studies were excluded because we were interested primarily in how human genetic heterogeneity contributed to the risk of AKI. Outpatient studies were excluded as AKI is primarily a disease of hospitalized patients.
Finally, the final criterion was included as we hoped to capture studies of AKI from ischemia or nephrotoxic injury, which are the commonest causes of AKI in hospitalized settings.
The titles and abstracts of the articles found by our search were screened using our selection criteria and articles of interest were selected for full article evaluation (figure 1); the bibliographies of relevant articles were also searched.
Full articles were then reviewed by two researchers (JL and UP) independently and a final selection was made; disagreements were discussed and a consensus decision was reached as to whether or not to include an article. On one article pertaining to AKI in preeclampsia(28), our discussion was inadequate to achieve consensus and a third researcher (CP) evaluated the study, which resulted in its exclusion.
Data Abstraction
The following data were extracted from each study: first author, journal, year of publication, number of cases/controls, ethnicity and the clinical setting in which AKI occurred. The gene polymorphisms or combinations thereof investigated by each of the studies were recorded, and the conclusions of the authors noted.
Primary and secondary endpoints of each study were recorded as well. Study quality parameters were also collected. Studies were scored in 10 categories, which are described in table 2 below. Each study then received an aggregate quality score using a system adapted from Clark et al. (29) Cohort studies were automatically given one point in the control group category to facilitate comparison; this was deemed acceptable as cohort studies are better for studying high prevalence conditions such as AKI. A study was scored as 'good' if the score was 8-10, 'fair' if the score was 5-7 and 'poor' if the score was <4. Our initial research proposal also included a plan to pool odds ratios and relative risks for individual genetic polymorphisms in a meta-analysis. Pooling of results was not undertaken, however, primarily because of marked heterogeneity in study populations as well as the definition of AKI for studies of specific genetic polymorphisms.
Results
Our search returned 7273 unique articles, of which 43 were retrieved for full article review based upon our screening of titles and abstracts. Reasons for the exclusion of studies can be found in figure Of the 16 included studies, 14 described genetic associations with AKI incidence (Table 3a) while 2 analyzed AKI outcomes (Table 3b ). All studies had a cohort or case-cohort design; 11 were prospective studies. All study populations were of mixed gender; 12 studies investigated adults, while 4 studied neonates. Only 9 of 
Inflammatory and Anti-Inflammatory Genes
Six different studies examined a total of fifteen polymorphisms in seven genes involved in inflammatory and anti-inflammatory pathways. Jaber et al. (19) , in a study of 61 patients with AKI requiring hemodialysis, found that high producers of TNF- (-308 A-allele carriers) possessed an increased risk of death after adjustment for APACHE II score (adjusted hazard ratio (HR)=2.5, p=0.04).
However, three other studies searched for an association between this polymorphism and AKI incidence, but found none. (13, 18, 20) The same study by Jaber et al. (19) (20) The IL-6 -174G/C polymorphism was investigated in three studies, of which only Guadino et al. (17) found a significant association. This study found that in patients undergoing CABG, IL-6 -174GG carriers had significantly higher elevations in perioperative creatinine vs. non-GG carriers (p<0.0001). However, Stafford-Smith et al. (13) found no such association in a similar population, nor did Treszl et al. (20) in VLBW infants.
Other Genes
Luo et al. (35) , in a population of 148 CABG patients, found that Haptoglobin 2-2 phenotype was associated with an increased risk of AKI (OR=5.4, p=0.03). In the HSP72 gene, Fekete et al. (34) found that VLBW infants homozygous for the G allele were at increased risk for AKI (OR=3.17, p<0.01). This same group also found that in the VEGF -2578 C/A polymorphism, VLBW infants homozygous for the A allele were protected against AKI (OR=0.2, p=0.021). (32) None of the remaining polymorphisms investigated were found to be significantly associated with AKI.(38, 39)
Gene-gene Interactions
There were four studies that investigated gene-gene interactions and their association with AKI. The combinations studied were mostly those that augmented inflammatory or down-regulated anti-inflammatory pathways (Table   5 ). Wattanathum et al. (40) found that the CGG haplotype involving three separate polymorphisms in the IL-10 gene (-592 C/A, +734 A/G and +3367 G/A) was associated with a greater degree of AKI in patients with sepsis from pneumonia. They postulated that this genotype is associated with lower antiinflammatory IL-10 production, thus causing increased renal dysfunction.
Jaber et al.(19) investigated whether the combination of pro-inflammatory alleles from the TNF- -308G/A and IL-10 -1082 G/A polymorphisms, namely the TNF-
-308 AA and IL-10 -1082 AA/AG genotypes, were associated with an increased risk for dialysis or death. They found that patients with these genotypes had an elevated risk for dialysis or death after adjustment for APACHE II score (adjusted HR=5.17, p=0.005). found that the combination of IL-6 -572C and TNF- -308A alleles were weakly associated (p=0.05) with AKI in Caucasians. This study also investigated the interaction between AGT+842T/C and IL-6 -572G/C polymorphisms, and found the combination to be significantly associated with AKI (p<0.0001).
TNF-α -308 G/A and IL-1b +3954 C/T no … NS
TNF-α -308 G/A and IL-10 -1082 G/A no … NS
IL-1b +3954 C/T and IL-6 -174 G/C no … NS
IL-1b +3954 C/T and IL-10 -1082 G/
Discussion
While there have been several descriptive reviews on this topic, (41) (42) (43) to our knowledge this is the first systematic review of genetic determinants of AKI. In summary, we found that there is no single polymorphism that can be conclusively described as a risk factor in AKI. The general dearth of studies, the lack of confirmatory studies and their overall mediocre quality led us to this conclusion.
Of the 35 individual polymorphisms whose association with AKI has been studied, only APO E e2/e3/e4 had a significant association in more than one Another problem that we have found is one that is somewhat unique to AKI, that is the lack of a gold standard outcome which has also contributed to study is advised, in that both the RIFLE and AKIN criteria were formed in order to maximize sensitivity for AKI. In particular, use of the most sensitive categories of these classification systems would result in unacceptable dilution of case groups with false positive subjects. Therefore, we recommend using stage 2 of the AKIN criteria (a 200% to 300% increase in serum creatinine, or <0.5mL/kg urine output for 12 hours) as a cutoff, which would allow the creation of case groups that are both highly specific and have a well-defined phenotype.
Studying outcomes such as dialysis or mortality would also alleviate this problem; however, due to the rarity of such events, an adequately powered study examining such outcomes may not be feasible.
Novel biomarkers of kidney injury that are currently under study are another potential tool to be used in creating a highly specific AKI phenotype. These 
